| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 01/13/2011 | US20110009316 Proteolysis resistant active vegf |
| 01/13/2011 | US20110009313 Polyethylene glycolated lactoferrin complex and method of producing the same |
| 01/13/2011 | US20110009312 Albumin Fusion Proteins |
| 01/13/2011 | US20110009311 Peptides and their utility in modulation of behavior of cells expressing alpha3 beta1 integrins |
| 01/13/2011 | US20110009310 Drug for treating states related to the inhibition of angiogenesis and/or endothelial cell proliferation |
| 01/13/2011 | US20110008842 Novel chimeric tnf ligands |
| 01/13/2011 | US20110008465 Sesquiterpene formulations, kits and methods of use thereof |
| 01/13/2011 | US20110008457 Compositions and methods for modulating lipid composition |
| 01/13/2011 | US20110008455 Crosslinked Protein Nanocrystals, Crosslinked Protein Nanoaggregates and Method of Preparation Thereof |
| 01/13/2011 | US20110008447 Carrier comprising nanodiamond |
| 01/13/2011 | US20110008432 Method for Treating a Patient in Need of Aspirin Therapy |
| 01/13/2011 | US20110008418 Compositions and Methods for the Treatment of Cancer |
| 01/13/2011 | US20110008409 Pharmaceutical preparation containing a gestagen, and kit and method for treating endometriosis using the preparation |
| 01/13/2011 | US20110008395 Mixed micelles including amphipathic conjugates of rna agents, and uses thereof |
| 01/13/2011 | US20110008393 Nucleic acids and corresponding proteins entitled 58p1d12 useful in treatment and detection of cancer |
| 01/13/2011 | US20110008386 Use of mva to treat prostate cancer |
| 01/13/2011 | US20110008373 Prodrugs of cc-1065 analogs |
| 01/13/2011 | US20110008372 Enhancement of light activated drug therapy through combination with other therapeutic agents |
| 01/13/2011 | US20110008371 Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders |
| 01/13/2011 | US20110008370 Novel use of flj25416 gene |
| 01/13/2011 | US20110008368 Methods of modulating the ox40 receptor to treat cancer |
| 01/13/2011 | US20110008367 Anti-vegf antibody |
| 01/13/2011 | US20110008366 Inhibition of versican with sirna and other molecules |
| 01/13/2011 | US20110008364 Antibodies to tgf-beta |
| 01/13/2011 | US20110008358 Human monoclonal antibodies that specifically bind igf-ii |
| 01/13/2011 | US20110008357 Antibodies that bind il-18 and methods of inhibiting il-18 activity |
| 01/13/2011 | US20110008355 Anti-flt3 antibodies |
| 01/13/2011 | US20110008354 Antibodies to apo-2 receptor polypeptides |
| 01/13/2011 | US20110008345 Antigen-binding constructs |
| 01/13/2011 | US20110008342 Compositions of humanized notch fusion proteins and methods of treatment |
| 01/13/2011 | US20110008338 Treatment of Autoimmune Diseases |
| 01/13/2011 | US20110008337 Treatment of Autoimmune Diseases |
| 01/13/2011 | US20110008336 Treatment of Autoimmune Diseases |
| 01/13/2011 | US20110008335 Methods and Compositions for Increasing the Efficiency of Therapeutic Antibodies Using NK Cell Potentiating Compounds |
| 01/13/2011 | US20110008333 Methods of inhibiting unwanted cell proliferation using hedgehog antagonists |
| 01/13/2011 | US20110008331 Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
| 01/13/2011 | US20110008327 Compositions including triciribine and epidermal growth factor receptor inhibitor compounds or salts thereof and methods of use thereof |
| 01/13/2011 | US20110008326 Binding agents directed against il-4 receptor for the treatment of tumors, inflammatory and immunological disorders |
| 01/13/2011 | US20110008324 Antibody Selective for a Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor and Uses Thereof |
| 01/13/2011 | US20110008322 Anti-c35 antibody combination therapies and methods |
| 01/13/2011 | US20110008320 Further Use of Protein Kinase N Beta |
| 01/13/2011 | US20110008319 Card domain containing polypeptides, encoding nucleic acids, and methods of use |
| 01/13/2011 | US20110008314 Methods of and compositions for inhibiting the proliferation of mammalian cells |
| 01/13/2011 | US20110008307 Cephalotaxine Alkaloid Compositions and Uses Thereof |
| 01/13/2011 | US20110008302 Compositions and methods for immortalizing cells and screening for anti-cancer agents |
| 01/13/2011 | US20110008300 Cryopreservation of Adipose Tissue for the Isolation of Mesenchymal Stem Cells |
| 01/13/2011 | US20110008298 Method of deriving progenitor cell line |
| 01/13/2011 | US20110008295 Simian adenoviruses sadv-36, -42.1, -42.2, and -44 and uses thereof |
| 01/13/2011 | US20110008294 Methods for treating cancer with mva |
| 01/13/2011 | US20110008287 Methods and means for the treatment of hpv induced intraepithelial neoplasias |
| 01/13/2011 | US20110008283 Interferon fusion proteins |
| 01/13/2011 | US20110008278 Modulators of paraptosis and related methods |
| 01/13/2011 | US20110008267 Pharmaceutical and Cosmeceutical Wash-Off Mousse Shampoo Compositions, Processes for Preparing the Same and Uses Thereof |
| 01/13/2011 | US20110008260 Use of Nanocrystals for Drug Delivery from a Balloon |
| 01/13/2011 | US20110008259 Modulators of cystic fibrosis transmembrane conductance regulator |
| 01/13/2011 | US20110008257 Inhibitors of bruton's tyrosine kinase |
| 01/13/2011 | US20110008251 Methods for Generating Stably Linked Complexes Composed of Homodimers, Homotetramers or Dimers of Dimers and Uses |
| 01/13/2011 | US20110008250 Treatment of Autoimmune Diseases |
| 01/13/2011 | US20110008249 Proteins with high immunoreactivity and method for their production |
| 01/13/2011 | DE102010026684A1 Hemmung des Überlebens von Knochenkrebs durch Cyclohexenonverbindungen aus Antrodia camphorata Inhibition of survival of bone cancer cyclohexenone from Antrodia camphorata by |
| 01/13/2011 | DE102009032902A1 Induktion von α-Helix-Konformationen in Proteinen und Peptiden Induction of α-helical conformations in proteins and peptides |
| 01/13/2011 | CA2767808A1 Compositions and methods for inhibition of cancers |
| 01/13/2011 | CA2767595A1 Vaccines with oncofetal antigen/ilrp-loaded autologous dendritic cells and uses thereof |
| 01/13/2011 | CA2767561A1 Oncolytic viruses and methods for treating neoplastic disorders |
| 01/13/2011 | CA2767556A1 Azabicyclo compound and salt thereof |
| 01/13/2011 | CA2767476A1 Indazolyl-substituted dihydroisoxazolopyridines and methods of use thereof |
| 01/13/2011 | CA2767442A1 Antibody having anti-cancer activity |
| 01/13/2011 | CA2767367A1 The use of two micrornas in lung cancer prognosis and drug preparation |
| 01/13/2011 | CA2767298A1 Cyclic triazo sodium channel blockers |
| 01/13/2011 | CA2767296A1 Cyclic triazo sodium channel blockers |
| 01/13/2011 | CA2767257A1 Stable crystalline polymorphs of the dipotassium salt of (s)-2-{4-[2-(2,4-diamino-quinazolin-6-yl)-ethyl]-benzoylamino}-4-methylene-penta nedioic acid |
| 01/13/2011 | CA2767253A1 Novel nucleic acid prodrugs and methods of use thereof |
| 01/13/2011 | CA2767149A1 Pegylated l-asparaginase |
| 01/13/2011 | CA2767079A1 Heterocyclic compounds as jak receptor and protein tyrosine kinase inhibitors |
| 01/13/2011 | CA2766937A1 Combined preparation for use as a medicament |
| 01/13/2011 | CA2765463A1 Methods for treating or preventing fatigue |
| 01/13/2011 | CA2765290A1 Metallic nanoparticles, preparation and uses thereof |
| 01/13/2011 | CA2765066A1 Compositions and methods for enhancing virus efficacy |
| 01/12/2011 | EP2273266A1 Parasporin-1 receptor and use thereof |
| 01/12/2011 | EP2272959A1 BMP-11 compositions |
| 01/12/2011 | EP2272869A2 Angiopoietin-2 specific binding agents |
| 01/12/2011 | EP2272854A1 Novel glycolipid and use thereof |
| 01/12/2011 | EP2272845A2 Benzophenone thiazole derivatives useful for inhibiting formation of microtubule and method for producing the same |
| 01/12/2011 | EP2272844A1 Five-membered ring compound |
| 01/12/2011 | EP2272840A1 Intermediate compound for the preparation of halichondrin analogs |
| 01/12/2011 | EP2272839A1 Intermediate compounds for the preparation of halichondrin analogs |
| 01/12/2011 | EP2272838A1 Fostriecin derivatives and the pharmaceutical uses thereof |
| 01/12/2011 | EP2272835A1 Novel five-membered ring compound |
| 01/12/2011 | EP2272538A1 Method of detecting bladder cancer |
| 01/12/2011 | EP2272537A2 Salts of conjugated psychotropic drugs and processes of preparing same |
| 01/12/2011 | EP2272534A2 Identification of tumour-associated cell surface antigens for diagnosis and therapy |
| 01/12/2011 | EP2272529A2 DNA vaccine combined with an inducer of tumor cell apoptosis |
| 01/12/2011 | EP2272528A2 DNA vaccine combined with an inducer of tumor cell apoptosis |
| 01/12/2011 | EP2272527A2 Combined DNA vaccine and biological modifiers for cancer therapy |
| 01/12/2011 | EP2272513A1 Pharmaceutical compositions for treating cancer |
| 01/12/2011 | EP2272512A1 Pharmaceutical compositions for treating cancer |
| 01/12/2011 | EP2272511A1 Combination comprising an iron chelator and an anti-neoplastic agent and use thereof |
| 01/12/2011 | EP2272504A2 Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| 01/12/2011 | EP2271757A2 Compositions and methods related to mir-16 and therapy of prostate cancer |
| 01/12/2011 | EP2271672A2 Immunoglobulin and/or toll-like receptor proteins associated with myelogenous haematological proliferative disorders and uses thereof |